General Atlantic led financing for Expedition Therapeutics, with participation from RA Capital and Vivo Capital. The company dosed its first patient in a Phase 2 COPD trial for EXPD-101, with Brett Zbar joining the board.
Expedition Therapeutics secured funding to advance EXPD-101, a Phase 2-ready oral DPP1 inhibitor, into global development for COPD and neutrophil-driven diseases. Sofinnova Investments and Novo Holdings co-led the financing.
Brett Zbar, MD, oversees General Atlantic’s Life Sciences sector as a Managing Director. Before joining in 2020, he held roles at Foresite Capital and Aisling Capital, focusing on healthcare investments.
Gabrielle Poirier leads clinical operations at Expedition Therapeutics, with over 25 years of experience in global clinical development across therapeutic areas. She previously managed a pre-eclampsia program at Comanche BioPharma.
Gorjan Hrustanovic, PhD, is a Partner at BVF Partners, overseeing biotech investments for private and public companies. He serves on the boards of Olema Pharmaceuticals, Kymera Therapeutics, Forward Therapeutics, and Plexium.
Ralph trained in internal medicine, pulmonary, and critical care medicine at Yale after attending Rush Medical College. He later worked in industry roles at Bayer, Pfizer, Immunex, and Amgen, focusing on asthma.
Expedition Therapeutics develops treatments for inflammatory and respiratory diseases, aiming to transform COPD care by addressing fundamental disease mechanisms.
